当前位置: X-MOL 学术Anti-Cancer Drugs › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Does bevacizumab carry a hope for metastatic triple-negative breast cancer in the era of immunotherapy?
Anti-Cancer Drugs ( IF 2.3 ) Pub Date : 2021-08-16 , DOI: 10.1097/cad.0000000000001192
Rehab F Mohamed 1 , HebatAllah M Bakri , Ola N Abdelfattah , Samir Eid
Affiliation  

Triple-negative breast cancer (TNBC) has a very high rate of recurrence. Our aim is to investigate the efficacy of bevacizumab, platinum and paclitaxel as first-line in metastatic TNBC (mTNBC). This study included 54 female patients with mTNBC. They received bevacizumab, carboplatin and paclitaxel every 21 day for six cycles then who progressed shifted to second-line chemotherapy and the responders continue another two cycles. The median progression-free survival (PFS) was 27 months [95% confidence interval (CI), 17.019-36.981]. There were two factors that affect PFS; visceral only metastasis (hazard ratio, 0.23; P = 0.05) and performance status 0 (hazard ratio = 0.16; P = 0.02) with C-index 0.77. The median overall survival (OS) was 55 months (95% CI, 38.973-71.027). There were two factors that affect OS; type of presentation (hazard ratio = 7.91; P = 0.02) and performance status 0 (hazard ratio = 0.12; P = 0.01) with C-index 0.73. In the final evaluation, three factors have their print on achieving either stable disease (SD) or complete response (CR). Patients having ≤3 sites of metastasis odds ratio (OR) 3.92 (P = 0.02), patients with visceral only metastasis OR was 13.20 (P = 0.001), those with performance status 0 had the highest OR 19.5 (P = 0.001) and the percentage of this prediction was 64.8, 70.4 and 70.4%, respectively. Bevacizumab, carboplatin and paclitaxel were well tolerated, continuation of bevacizumab is recommended as long as SD or CR responses are obtained and tolerated.

中文翻译:

免疫治疗时代,贝伐珠单抗是否为转移性三阴性乳腺癌带来希望?

三阴性乳腺癌(TNBC)的复发率非常高。我们的目的是研究贝伐珠单抗、铂类药物和紫杉醇作为一线治疗转移性 TNBC (mTNBC) 的疗效。这项研究包括 54 名 mTNBC 女性患者。他们每 21 天接受贝伐单抗、卡铂和紫杉醇治疗,持续六个周期,然后进展的患者转向二线化疗,反应者继续另外两个周期。中位无进展生存期 (PFS) 为 27 个月 [95% 置信区间 (CI),17.019-36.981]。影响 PFS 的因素有两个:仅内脏转移(风险比,0.23;P = 0.05),性能状态为 0(风险比 = 0.16;P = 0.02),C 指数为 0.77。中位总生存期 (OS) 为 55 个月(95% CI,38.973-71.027)。影响 OS 的因素有两个;表现类型(风险比 = 7.91;P = 0.02)和表现状态 0(风险比 = 0.12;P = 0.01),C 指数 0.73。在最终评估中,三个因素对实现疾病稳定(SD)或完全缓解(CR)有影响。转移部位≤3个的患者比值比(OR)为3.92(P = 0.02),仅内脏转移的患者比值比为13.20(P = 0.001),体能状态为0的患者比值比最高为19.5(P = 0.001),这一预测的百分比分别为 64.8%、70.4% 和 70.4%。贝伐珠单抗、卡铂和紫杉醇的耐受性良好,只要获得 SD 或 CR 反应并能耐受,建议继续使用贝伐珠单抗。
更新日期:2021-08-16
down
wechat
bug